Hackensack, New Jersey
Phase 1 cancer trials in Hackensack, NJ
40 Phase 1 cancer studies are recruiting participants at sites in Hackensack as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Hackensack at a glance
- 40 studies are recruiting at a site in Hackensack.
- By phase: Phase 1 (19), Phase 1/2 (21).
- By sponsor: industry (37), university, hospital or other (3).
- By research area: Lung Cancer (21), Breast Cancer (9), Lymphoma (8), Prostate Cancer (2).
- Most recent update to one of these records: November 17, 2026.
Breast cancer studies recruiting in Hackensack
Basic details from each study's public record (the 30 most recently updated of 40). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Hackensack University Medical Center
- Registry record
- NCT07488676 · updated
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Phase 1
- Ages 19 and older
- All sexes
- Sponsor
- NiKang Therapeutics, Inc.
- Study site
- John Theurer Cancer Center at Hackensack UMC
- Registry record
- NCT06586957 · updated
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- John Theurer Cancer Center at Hackensack University Medical Center
- Registry record
- NCT07287995 · updated
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- John Theurer Cancer Center at Hackensack University Medical Center
- Registry record
- NCT06618287 · updated
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Normunity AccelCo, Inc.
- Study site
- Normunity Investigational Site
- Registry record
- NCT07182149 · updated
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- John Theurer Cancer Center
- Registry record
- NCT04895709 · updated
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Vironexis Biotherapeutics Inc.
- Study site
- Hackensack Medical Center
- Registry record
- NCT07192432 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Hackensack, NJ on ClinicalTrials.gov.
Lung cancer studies recruiting in Hackensack
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- SystImmune Inc.
- Study site
- John Theurer Cancer Center-Hackensack
- Registry record
- NCT07080242 · updated
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101)
- Registry record
- NCT07227597 · updated
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- John Theurer Cancer Center at Hackensack University Medical Center
- Registry record
- NCT07397338 · updated
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- John Theurer Cancer Center at Hackensack UMC
- Registry record
- NCT07542704 · updated
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Inc
- Study site
- Hackensack University Medical Center
- Registry record
- NCT07094204 · updated
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Alentis Therapeutics AG
- Study site
- Hackensack University Medical Center
- Registry record
- NCT06747585 · updated
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Study site
- Hackensack University Medical Center
- Registry record
- NCT06179069 · updated
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Moonlight Bio, Inc
- Study site
- Hackensack University Medical Center
- Registry record
- NCT07488923 · updated
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Hackensack University Medical Center · John Theurer Cancer Center at Hackensack University Medical Center · Newman Street Imaging
- Registry record
- NCT07227298 · updated
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103)
- Registry record
- NCT06780137 · updated
A Study of ZW251 in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Zymeworks BC Inc.
- Study site
- Hackensack University Medical Center
- Registry record
- NCT07164313 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #105
- Registry record
- NCT05176483 · updated
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Daiichi Sankyo
- Study site
- John Theurer Cancer Center At Hackensack Umc
- Registry record
- NCT06362252 · updated
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- John Theurer Cancer Center at Hackensack UMC
- Registry record
- NCT06892548 · updated
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Whitehawk Therapeutics, Inc.
- Study site
- Hackensack University Medical Center - John Theurer Cancer Center
- Registry record
- NCT07444814 · updated
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- John Theurer Cancer Center at Hackensack University Medical Center
- Registry record
- NCT06764771 · updated
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Hackensack University Medical Center
- Registry record
- NCT06179160 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Hackensack, NJ on ClinicalTrials.gov.
Prostate cancer studies recruiting in Hackensack
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- John Theurer Cancer Center
- Registry record
- NCT07543055 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Hackensack, NJ on ClinicalTrials.gov.
Lymphoma studies recruiting in Hackensack
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Phase 1/2
- Up to age 22
- All sexes
- Sponsor
- PedAL BCU, LLC
- Study site
- Hackensack University Medical Center
- Registry record
- NCT04726241 · updated
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT06564038 · updated
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT06542250 · updated
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Phase 1
- Ages 12 to 78
- All sexes
- Sponsor
- Orca Biosystems, Inc.
- Study site
- John Theurer Cancer Center at Hackensack University Medical Center
- Registry record
- NCT03802695 · updated
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- John Theurer Cancer Center Hackensack University Medical Center
- Registry record
- NCT05826535 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Hackensack, NJ on ClinicalTrials.gov.
Ask about studies near Hackensack
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections